Statistical analysis on ADAS-cog was performed using all available on-treatment data. Beginning with Month 3, there were 127 subjects in the placebo group and 126 subjects in the 5 mg/day dose group ...

On Monday April 29, Annovis Bio announced their phase 2/3 Alzheimer's Disease trial results, causing stock to drop ~60%. Of the five pre-specified efficacy endpoints, only ADAS-Cog11 results were ...

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of investigational therapies and diagnostic assays for patients with Alzheimer’s disease (AD) and other ...

On Sunday, July 28th, Anavex Life Sciences announced that data from their phase 2b/3 Alzheimer's Disease trial was presented at the 2024 Alzheimer's Association International Conference. New data can ...

Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild AD Improvement in cognition measured by ADAS-Cog 11 at three months is ...

Data presented at CTAD showed strong separation from placebo and statistical significance in mild-to-moderate patients on key global, cognitive, and behavioral measures including CDR-SB, ADAS- Cog 11 ...

September 13, 2011 — In a pilot study, a nasal spray form of insulin, used daily for 4 months, stabilized or improved cognition, function, and cerebral glucose metabolism in adults with amnestic mild ...